CMMB · Chemomab Therapeutics
The AI's read
The FDA's feedback supports Chemomab's planned rheumatoid arthritis study, and the proposed Scipher merger has a target closing date. The share sale provides funds for operations through the first quarter of 2027. But the quarterly loss grew from a year earlier, and the update gives no trial results or completed merger. These facts point in different directions, so the update does not clearly change the company's outlook.